Eric K. Rowinsky, M.D., has served as the Head of Research and Development and Chief Medical Officer of Stemline Therapeutics, Inc., since January 2012 and as a board member of Biogen Idec since 2010. Dr. Rowinsky is also an Adjunct Professor of Medicine at New York University and has been an independent consultant since January 2010. Prior to that, he was the Chief Medical Officer of Primrose Therapeutics, Inc. from August 2010 until its acquisition in September 2011. From 2005 to December 2009, he served as the Chief Medical Officer and Executive Vice President of ImClone Systems Incorporated. From 1996 to 2004, Dr. Rowinsky held several positions at the Cancer Therapy & Research Center’s Institute for Drug Development, including Director of the Institute and Director of Clinical Research. From 1988 to 1996, Dr. Rowinsky was an Associate Professor of Oncology at the Johns Hopkins School of Medicine and on the staff of the Johns Hopkins Hospital. Dr. Rowinsky is also a member of the boards of directors of Coronado Biosciences, Inc. and Navidea Biopharmaceuticals, Inc. Dr. Rowinsky earned his medical degree from Vanderbilt University School of Medicine and a fellowship in medical oncology from the Johns Hopkins University.
Amy W. Schulman joined Arsia Therapeutics as Chief Executive Officer in August of 2014, at the same time she began her role as a Venture Partner at Polaris Partners. Ms. Schulman is also a Senior Lecturer at Harvard Business School, where she was appointed to the faculty in July of 2014. Prior to this, she joined Pfizer Inc. in 2008 and served as Executive Vice President and General Counsel and the Business Unit Lead for Pfizer’s Consumer Healthcare business until December 2013. Before joining Pfizer, she was a partner at DLA Piper, where she was a member of the Board and Executive Policy Committees. Ms. Schulman is a Phi Beta Kappa graduate of Wesleyan University and earned her J.D. from Yale Law School in 1989. She serves on the Board of Directors of Alnylam, The Brookings Institution and Wesleyan University.
Yurii Udaltsov, Cand. Sc. has served as a member of our board of directors since November 2011. Dr. Udaltsov is Director of Innovative Development and member of the management board of RUSNANO Corporation, positions he has held since January 2009 and February 2009, respectively. From 2004 to December 2008, he was Head of the Reform Management Center of RAO UES, the Unified Energy System of Russia. Dr. Udaltsov received his undergraduate degree as an Engineer-physicist at the Moscow Institute of Physics and Technology and Candidate of Science degree at the Computing Center of RAS.